Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genscript Biotech ( (HK:1548) ) has provided an update.
Genscript Biotech Corporation announced the grant of 774,960 Share Awards under its 2019 RSU Scheme to an executive director and employee grantees. This move is part of the company’s strategy to align employee incentives with performance, featuring a vesting period of approximately three years and a clawback mechanism to ensure compliance with performance targets. The initiative reflects Genscript’s commitment to fostering employee engagement and maintaining robust corporate governance.
The most recent analyst rating on (HK:1548) stock is a Buy with a HK$24.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, operating in the biotechnology industry. The company focuses on providing innovative products and services, including gene synthesis, peptide synthesis, protein production, and antibody development, catering to various sectors within the life sciences market.
YTD Price Performance: 73.37%
Average Trading Volume: 23,824,351
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.08B
See more insights into 1548 stock on TipRanks’ Stock Analysis page.